ERBB2 and small cell lung carcinoma: Of the cancer drugs that have received accelerated approval thus far, 17 have been either withdrawn by the FDA (e.g., bevacizumab for HER2-negative breast cancer) or voluntarily withdrawn by the manufacturer (e.g., nivolumab and pembrolizumab for small cell lung cancer (SCLC)) after failing to prove a clinical benefit in the post-approval trial [21,22].